The Role of CMAs in Quality by Design (QbD): Quality cannot be tested into a product. It must be designed into it. In the QbD paradigm, Critical Material Attributes (CMAs) are the variables that determine whether that design holds or collapses when raw materials arrive at your dock.
CMA vs. CQA: Understanding the Difference in Pharmaceutical Technology Transfer: Conflating input material attributes with output product characteristics is a quiet but persistent source of scale-up failure.
Is Science the true starting point for innovation? Discover why the linear model is failing and how the dynamic cycle of Manufacturing, Science, and Technology Transfer is the real engine of progress.
Building Once, Validating Forever: Why Scalable CQV Is the Future-Proof Strategy Life Sciences Manufacturers Can’t Ignore – Scalability is the difference between a validation program that becomes a growing liability and one that becomes a strategic asset as your operation expands.
The Future of the Modern Laboratory Is Here: Introducing Mivado GlobalPerformance’s AI-Driven LIMS – In today’s fast-paced scientific and industrial landscape, laboratories are under more pressure than ever to deliver faster results and maintain airtight compliance.
Tagged : AI, AI-LIMS, APQR, Biopharma, Biopharmaceutical, Compliance, Digital Transformation, Digitalization, GxP, Health Canada, LIMS, Quality 4.0